Yup, China currently has more foundational advantages in biotech than it does in AI - a larger population, less institutional regulations & red tape, and far less excessive medical expenses from artificial labor shortages (e.g. the doctors deficit). The only thing it historically lacked is capital, but that's been changing as Big Medicine is realizing that it's much more efficient to invest in Chinese companies.
By contrast, AI is held back by the lack of a truly globally successful software ecosystem (the rest of the world runs on Nvidia, Cuda, Google, etc.) and the chips embargo. No such problems in medicine where regulatory frameworks tend to be local and prohibitively expensive prices make it harder for Western companies to achieve economies of scale. China has huge chances here to be globally dominant, IMO.